Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional chemotherapy or a second transplant, with no ...
Application of auto-SCT in the post-remission therapy for adolescents and young adults (AYAs) with ALL is controversial. We analyzed the outcomes of 79 AYAs (15–24 years) with ALL who received our ...
One of the hottest debates in biotech today involves cell therapy. Autologus cell therapies—treatments made by engineering a patient’s own immune cells—established the field. But making such ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results